 |
PDBsum entry 3m3c
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
Faseb J
24:3861-3868
(2010)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural insights into the recognition mechanism between an antitumor galectin AAL and the Thomsen-Friedenreich antigen.
|
|
L.Feng,
H.Sun,
Y.Zhang,
D.F.Li,
D.C.Wang.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Thomsen-Friedenreich (TF) antigen, which plays an important role in the
regulation of cancer cell proliferation, occurs in approximately 90% of all
human cancers and precancerous conditions. Although TF antigen has been known
for almost 80 yr as a pancarcinoma antigen, the recognition mechanism between TF
antigen and target protein has not been structurally characterized. A number of
studies indicated that TF disaccharide is a potential ligand of the
galactoside-binding galectins. In this work, we identified the TF antigen as a
potential ligand of the antitumor galectin AAL (Agrocybe aegerita lectin)
through glycan array analysis and reported the crystal structure of AAL
complexed with the TF antigen. The structure provides a first look at the
recognition mode between AAL and TF antigen, which is unique in a conservative
(Glu-water-Arg-water) structural motif-based hydrogen bond network.
Structure-based mutagenesis analysis further revealed the residues responsible
for recognition specificity and binding affinity. Crystal structures of AAL
complexed with two other TF-containing glycans showed that the unique TF
recognition mode is kept intact, which may be commonly adopted in some
cancer-related galectins. The finding provided the new target and approach for
the antitumor drug design and relative strategy based on the AAL-TF recognition
mode as a prototype model.-Feng, L., Sun, H., Zhang, Y., Li, D.-F., Wang, D.-C.
Structural insights into the recognition mechanism between an antitumor galectin
AAL and the Thomsen-Friedenreich antigen.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |